A Phase I/II Study of Nintedanib and Capecitabine in Refractory Metastatic Colorectal Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Nintedanib (Primary) ; Capecitabine
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 08 Aug 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Oct 2017.
- 08 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Jun 2017 Planned End Date changed from 1 Feb 2018 to 1 Aug 2018.